Semaglutide may lead to gastrointestinal problems, such as nausea, diarrhea, or constipation
On one hand, it can degrade intestinal mucin glycoproteins by enzymes (such as glycoside hydrolases, proteases, sulfatases, and sialidases) to produce SCFAs, acetates, propionates, and 1,2-propanediol, as well as succinates and sulfates, promoting mucin turnover and thickening, thereby enhancing intestinal barrier function and reducing the permeability of gut microbiota products
While the results of the study are encouraging, the researchers caution that the research is in the early stages
Most research-based protocols suggest starting at a conservative dose and titrating based on individual tolerance and response